Skip to main content
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. — Investor Relations & Filings

Ticker · APRE ISIN · US03836J1025 US Professional, scientific and technical activities
Open in API
Filings indexed 405 across all filing types
Latest filing 2019-09-30 Regulatory Filings
Country US United States of America
Listing US APRE

About Aprea Therapeutics, Inc.

https://www.aprea.com/

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel cancer therapeutics. The company focuses on precision oncology through a synthetic lethality-based approach, targeting DNA Damage Response (DDR) pathways. Its pipeline consists of small molecule therapeutics designed to exploit vulnerabilities associated with cancer cell mutations, aiming to maximize clinical activity and selectivity while minimizing toxicity. Aprea Therapeutics is conducting clinical trials to evaluate its programs in patients with advanced solid tumors.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the U.S. Securities and Exchange Commission requesting acceleration of the effective date for a Registration Statement on Form S-1. It is a formal communication related to the registration process for securities, specifically requesting the SEC to declare the Form S-1 effective earlier than the standard timeline. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory communication related to capital raising and securities registration, but it is not the registration statement itself or a financial report. Given the nature of the document as a regulatory filing related to securities registration and acceleration request, it fits best under Regulatory Filings (RNS). The document length is short and it is a letter, not a report or presentation.
2019-09-30 English
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It includes details about the securities to be registered and the registrant's information. This form is not a financial report, earnings release, or any other type of report but a regulatory filing related to securities registration. The document length is 3576 characters, and it is a standalone filing for registration purposes. Therefore, it fits best under Regulatory Filings (RNS).
2019-09-30 English
S-1/A
Regulatory Filings Classification · 100% confidence The document is titled as an Amendment No. 3 to Form S-1 Registration Statement filed with the SEC, dated September 27, 2019. It is a registration statement under the Securities Act of 1933 for Aprea Therapeutics, Inc. The text includes details about the offering of common stock, underwriting, corporate reorganization, and other typical elements of an IPO prospectus. The document is not a financial report, earnings release, or management discussion but a regulatory filing related to securities registration and offering. Therefore, it fits the category of a Regulatory Filing (RNS) rather than a financial report or other specific filing type.
2019-09-28 English
Regulatory Filings 2019
Regulatory Filings
2019-09-26 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm to the U.S. Securities and Exchange Commission regarding comments on an Amendment No. 1 to a Registration Statement on Form S-1 filed by Aprea Therapeutics, Inc. The letter addresses SEC staff comments and responses related to the registration statement, including exhibit disclosures and confidential treatment requests. The document is a correspondence related to regulatory review and filing amendments, not the registration statement itself or a financial report. It is also short (3,729 characters) and serves as a response to SEC comments rather than a standalone report or financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other specific categories.
2019-09-25 English
S-1/A
Regulatory Filings Classification · 95% confidence The document is an Amendment No. 2 to a Form S-1 Registration Statement filed with the SEC, which is a regulatory filing related to the registration of securities for public offering. It includes details about the registration, indemnification of directors and officers, and expenses related to the offering. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains detailed regulatory information rather than just an announcement or certification, so it is not an RPA or a certification document.
2019-09-25 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.